ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025

What: ANI Pharma's insider sold **4,772** shares, indicating a potential shift in confidence.
Why: The sale comes as the company's revenue reached **$883 million** in 2025, a notable milestone.
Signal: The insider sale may signal a decrease in the company's growth prospects, despite stable revenue.
Target: The company's focus on branded and generic pharmaceuticals positions it for long-term growth, with a potential target market of **$1.2 billion** in 2027.
Risk: The insider sale increases the risk of a potential stock price decline, as investors may view it as a negative signal.